Stocks · News reference
RAmylyx Pharma Q2 EPS $(0.39) Misses $(0.36) Estimate, Cash & Equivalents $279.8M. Cash runway Expected To Fund Operations Till 2028
Amylyx Pharma (NASDAQ:AMLX) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.36) by 8.33 percent. This is a 15.22 percent increase over losses of $(0.46) per share from
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 6, 2026, 11:06 AM
- Checked
- Aug 6, 2026, 11:06 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Benzinga Bulls and Bears: Ross, Moderna, Webull
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
Read original at benzinga8-K filing — Amylyx Pharmaceuticals, Inc. (AMLX)
Filed: 2026-08-20 AccNo: 0001193125-26-359418 Size: 411 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Read original at edgarReported Earlier, Amylyx Pharmaceuticals Prices Upsized $500M Public Offering Of 14,090,000 Common Shares At $35.50 Per Share
Read original at benzinga